IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review

Toxoplasma gondii infection can lead to severe disease in immunocompromised patients. Current systemic therapies in psoriasis rely on varying degrees of immunomodulation. Few studies have investigated the involvement of key cytokines targeted by these novel therapies (interleukins 23 and 17) in the...

Full description

Saved in:
Bibliographic Details
Main Authors: J. Dagher, J. Ringuet
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:SAGE Open Medical Case Reports
Online Access:https://doi.org/10.1177/2050313X251320196
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850196675723788288
author J. Dagher
J. Ringuet
author_facet J. Dagher
J. Ringuet
author_sort J. Dagher
collection DOAJ
description Toxoplasma gondii infection can lead to severe disease in immunocompromised patients. Current systemic therapies in psoriasis rely on varying degrees of immunomodulation. Few studies have investigated the involvement of key cytokines targeted by these novel therapies (interleukins 23 and 17) in the immune response against T. gondii . We describe a case of a patient with severe plaque psoriasis and a history of frequent ocular toxoplasmosis reactivations successfully treated using anti-IL-23 therapy without T. gondii reactivation. A brief scoping review of the literature is presented to address current data on toxoplasmosis and biologic therapy for psoriasis.
format Article
id doaj-art-6329c6b9a7264509a1a8e4bfd8a06d98
institution OA Journals
issn 2050-313X
language English
publishDate 2025-02-01
publisher SAGE Publishing
record_format Article
series SAGE Open Medical Case Reports
spelling doaj-art-6329c6b9a7264509a1a8e4bfd8a06d982025-08-20T02:13:23ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2025-02-011310.1177/2050313X251320196IL-23 blockade in a patient with psoriasis and reactivation history: Case report and reviewJ. Dagher0J. Ringuet1Mailman School of Public Health, Columbia University, New York City, NY, USACentre de Recherche Dermatologique de Québec, Quebec City, QC, CanadaToxoplasma gondii infection can lead to severe disease in immunocompromised patients. Current systemic therapies in psoriasis rely on varying degrees of immunomodulation. Few studies have investigated the involvement of key cytokines targeted by these novel therapies (interleukins 23 and 17) in the immune response against T. gondii . We describe a case of a patient with severe plaque psoriasis and a history of frequent ocular toxoplasmosis reactivations successfully treated using anti-IL-23 therapy without T. gondii reactivation. A brief scoping review of the literature is presented to address current data on toxoplasmosis and biologic therapy for psoriasis.https://doi.org/10.1177/2050313X251320196
spellingShingle J. Dagher
J. Ringuet
IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review
SAGE Open Medical Case Reports
title IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review
title_full IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review
title_fullStr IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review
title_full_unstemmed IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review
title_short IL-23 blockade in a patient with psoriasis and reactivation history: Case report and review
title_sort il 23 blockade in a patient with psoriasis and reactivation history case report and review
url https://doi.org/10.1177/2050313X251320196
work_keys_str_mv AT jdagher il23blockadeinapatientwithpsoriasisandreactivationhistorycasereportandreview
AT jringuet il23blockadeinapatientwithpsoriasisandreactivationhistorycasereportandreview